Novartis' Sandoz doubles down on antibiotics with $500M deal for GSK brands

Novartis’ Sandoz is doubling down on antibiotics with a hefty deal for GlaxoSmithKline’s cephalosporin business.

Generics-focused Sandoz will pay $350 million up front and up to $150 million in milestone payments for Zinnat, Zinacef and Fortum, established antibiotic brands sold in more than 100 countries.